Interrogating the tumor microenvironment (TME) in patients (pts) with head and neck mucosal squamous cell carcinoma (HNmSCC) treated with programmed death-1 (PD-1) inhibitors

被引：0
|
作者：
Ferguson, Angela L.
Beddow, Thomas
Patrick, Ellis
Willie, Elijah
Elliott, Michael
Low, Tsu-Hui
Wykes, James
Palme, Carsten
Clark, Jonathan
Hui, Mun Ngah
Palendira, Umaimainthan
Gupta, Ruta
Lee, Jenny H. J.
机构：
[1] Univ Sydney, Centenary Inst, Sydney, NSW, Australia
[2] Univ Sydney, Sydney, NSW, Australia
[3] Chris OBrien Lifehouse, Sydney, NSW, Australia
[4] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[5] NSW Hlth Pathol, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6048
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients
    Goltz, Diane
    Gevensleben, Heidrun
    Dietrich, Joern
    Schroeck, Friederike
    de Vos, Luka
    Droege, Freya
    Kristiansen, Glen
    Schroeck, Andreas
    Landsberg, Jennifer
    Bootz, Friedrich
    Dietrich, Dimo
    ONCOTARGET, 2017, 8 (25) : 41011 - 41020
  • [32] Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
    Mallett, Grace
    Laurence, Arian
    Amarnath, Shoba
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)
  • [33] Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
    Prasad, Vinay
    Kaestner, Victoria
    SEMINARS IN ONCOLOGY, 2017, 44 (02) : 132 - 135
  • [34] PROGRAMMED CELL DEATH PROTEIN (PD-1) BLOCKADE IN ADVANCED AND METASTATIC SQUAMOUS CELL CARCINOMA OF THE SKIN
    Vaidya, P.
    Lin, S.
    In, G.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 : A196 - A196
  • [35] Interim analysis of phase 2 results for Cemiplimab, a human monoclonal antibody to programmed death-1 (PD-1), in patients with locally advanced cutaneous squamous cell carcinoma
    Migden, M. R.
    Berking, C.
    Chang, A. L. S.
    Eigentler, T. K.
    Hauschild, A.
    Hernandez-Aya, L.
    Khushalani, N., I
    Lewis, K. D.
    Meier, F.
    Modi, B.
    Rischin, D.
    Schadendorf, D.
    Schmults, C. D.
    Ulrich, C.
    Booth, J.
    Li, S.
    Mohan, K.
    Stankevich, E.
    Lowy, I
    Fury, M. G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 161 - 162
  • [36] Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction
    Wang, Yu
    Huang, Kun
    Gao, Yali
    Yuan, Dandan
    Ling, Lin
    Liu, Jieqing
    Wu, Sihai
    Chen, Roufen
    Li, He
    Xiong, Yizu
    Liu, Han
    Ma, Junjie
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 229
  • [37] FACTORS EVALUATED AS PREDICTORS OF EXCEPTIONAL RESPONSE TO PD-1 INHIBITORS IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CANCER
    Song, Alexander
    Ng, Ron
    Heller, John
    Petro, Robin
    D'Agostino, Ralph
    Lycan, Thomas
    Porosnicu, Mercedes
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A151 - A151
  • [38] Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression
    Denaro, Nerina
    Merlano, Marco Carlo
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (03): : E42 - E47
  • [39] Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
    Pawlowska, Anna
    Suszczyk, Dorota
    Tarkowski, Rafal
    Paduch, Roman
    Kotarski, Jan
    Wertel, Iwona
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 9691 - 9709
  • [40] Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma
    Chang, Mark
    Song, Alexander
    Deyo, Logan James
    Stamos, Daniel
    Bloomer, Chance H.
    Khoury, Lara M.
    Porosnicu, Mercedes
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345